Tonix Pharmaceuticals Holding Corp. Cash Flow Statement
TNXP|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$61M
FY2025
Free Cash Flow
-$61M
FY2025
Capital Expenditures
$120,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Tonix Pharmaceuticals Holding Corp. used $61M in operating cash flow and negative free cash flow of $61M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$130.0M | -$116.7M | -$110.2M |
| Depreciation & Amortization | $3.4M | $4.3M | $1.3M |
| Operating Cash Flow | -$60.9M | -$102.0M | -$98.1M |
| Capital Expenditures | $120.0K | $7.9M | $48.1M |
| Free Cash Flow | -$61.0M | -$109.9M | -$146.2M |
| Share Buybacks | $13.8M | $14.0M | $14.0M |
| FCF Margin | -604.8% | -1414.8% | -1882.1% |